A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?: Erratum

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709271/
https://www.ncbi.nlm.nih.gov/pubmed/31393415
http://dx.doi.org/10.1097/MD.0000000000016824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709271/
https://www.ncbi.nlm.nih.gov/pubmed/31393415
http://dx.doi.org/10.1097/MD.0000000000016824

Ejemplares similares